Indomethacin for Growth

Neonatal Bartter syndrome differs from the classical Bartter syndrome in the occurrence of antenatal presentation with polyhydramnios. Nephrocalcinosis and severe growth retardation are common sequelae. Indomethacin has been reported to improve linear growth, but its use in the early newborn period has been infrequently described.

In this paper we report normal growth and development and the absence of nephrocalcinosis in an infant now aged 19 months with neonatal Bartter syndrome treated from day 3 of life with indomethacin. With early diagnosis and treatment with indomethacin plus adequate water, calories, and sodium, normal growth can be achieved and nephrocalcinosis may be prevented in children with neonatal Bartter syndrome. Abstract Volume 10 Issue 6 (1996) pp 756-758 Neonatal Bartter syndrome – use of indomethacin in the newborn period and prevention of growth failure

F. E. Mackie, E. M. Hodson,
L. P. Roy,
J. F. Knight Centre for Kidney Research,
Royal Alexandra Hospital for Children,
Sydney, Australia

Received September 12, 1995; received in revised form April 22, 1996; accepted May 8, 1996

Print This Post Print This Post